Click here to close now.

Welcome!

.NET Authors: Elizabeth White, Pat Romanski, Andreas Grabner, Trevor Parsons, Tad Anderson

News Feed Item

Biostar Pharmaceuticals, Inc. Announces 2012 Third Quarter Financial Results

2012 Third Quarter Net Sales Increase by 22% vs. 2012 Second Quarter

XIANYANG, China, Nov. 19, 2012 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter and nine months ended September 30, 2012.   Biostar's overall results continued to be affected by the temporary PRC government imposed suspension of gel capsule sales earlier this year.

Third Quarter 2012 vs. Third Quarter 2011*

  • Net sales decreased to $10.0 million from $24.8 million
  • Gross margin decreased to 52.6% as compared to 69.9%;
  • Loss from operations was $5.8 million, as compared to income from operations of $5.9 million; and,
  • The net loss was $5.9 million, or $0.63 per diluted share, as compared to net income of $4.5 million, or $0.47 per diluted share. 

Nine Months 2012 vs. Nine Months 2011*

  • Net sales decreased to $34.0 million from $66.0 million
  • Gross margin decreased to 60.7% as compared to 71.1%;
  • Loss from operations was $14.8 million, as compared to income from operations of $15.6 million; and,
  • The net loss was $13.3 million, or $1.41 per diluted share, as compared to net income of $11.3 million, or $1.22 per diluted share. 

*Per share amounts for both periods reflect the reverse split effective April 3, 2012. 

Net Sales by Product/Facility 

$ in millions

For the nine month period ended 9/30

Xin Aoxing product (1)

(at Xianyang Facility)

All other Xianyang Facility products (1)

Weinan Facility

products (2)

Hospital products (3)

(at Xianyang Facility)

2012

2011

% change

2012

2011

% change

2012

2011

% change

2012

2011

% change

Net Sales                   

$16.3

$44.5

(63.4%)

$11.1

$21.5

(48.2%)

$5.3

-

100%

$1.3

-

100%

% of Total Net Sales

47.9%

67.5%


32.8%

32.5%


15.5%

-


3.8%

-



(1)
Biostar's products are manufactured at two facilities: Xianyang and Weinan.  Xin Aoxing, the Company's flagship product, is manufactured at the Xianyang facility.


(2)
 There were no sales reported in the third quarter and nine months of 2011 because the Weinan facility was acquired in October 2011.


(3)
Products manufactured at the Xianyang facility and exclusively sold to Xijing Hospital, as per an agreement signed in September 2012.

Ronghua Wang, Biostar's Chief Executive Officer and Chairman commented, "Although as expected, our 2012 third quarter overall results were below those of the 2011 third quarter, our business has shown signs of recovery and net sales for the current quarter increased by approximately $1.8 million, or 22% as compared to the 2012 second quarter.

"Following a temporary industry-wide suspension of gel capsules sales earlier this year by the State Food and Drug Administration (SFDA), on July 30, 2012, we received the "green-light" approval from Xianyang SFDA authorities to restart sales of gel capsule products.  In anticipation of the receipt of the approval, our management team met to design, develop and implement a plan to accelerate the recovery of our business.  As a result, we:   

  • Ramped up production by adding a second shift;
  • Initiated an aggressive advertising campaign to rebuild consumer and physician confidence in our products and established incentives for the sales force in all distribution offices nationwide; 
  • In early September, we added a new dimension to our sales model by establishing a Business-to-Customer (B2C) call center, which is currently operational; and,
  • Increased efforts to complete several experimental tests for Xijing Hospital, which resulted in the signing of two one-year contracts valued at approximately $3.6 million and $3.0 million, respectively, to manufacture a total of eight drugs specifically for the needs of Xijing Hospital."

Mr. Wang continued, "Net sales for the 2012 third quarter and nine month periods of our flagship gel capsule product Xin Aoxing substantially decreased as did net sales for all other gel capsule products.   However, that was partially offset by:

  1. Net sales of approximately $1.3 million in 2012 third quarter resulting from shipments to Xijing Hospital.
  2. Net sales from our Weinan facility which accounted for approximately $2.0 million or 19.7% and approximately $5.3 million or 15.5% of sales for the 2012 third quarter and nine month period, respectively.  The Weinan facility was acquired during the fourth quarter of 2011 hence there were no sales recorded in the 2011 periods.

"Gross margin for the 2012 third quarter and nine month periods declined mainly due to substantially lower net sales for Xin Aoxing, which historically has been our highest margin product.  Also our gross margin for both periods was negatively affected by lower selling prices due to fierce competition and by the PRC government's essential drug list price control policy.

"As a  percentage of net sales, 2012 third quarter selling expenses and general expenses increased to approximately 60% and 26%, respectively as compared to approximately 42% and 4%, respectively, in the same period of 2011, mainly due to lower sales.  Similarly, selling expenses and general expenses as percentage of net sales for the 2012 nine month period, increased as compared to the same period of 2011.  R&D expenses for the 2012 third quarter and nine months accounted for 8% and 7% of total net sales, respectively.  Of note, in 2012 we reclassified long-term deposits into current assets and amortized R&D quarterly; we did not incur quarterly R&D expenses in 2011, as R&D expense was recorded as a long-term deposit at December 31, 2011.   Additionally, in the 2012 third quarter, we paid the local government a one-time, non-appealable administrative penalty of approximately $1.6 million related to the gel capsule incident."

Biostar's CFO, Zack Pan noted, "Our balance sheet remains strong.  Total current assets at September 30, 2012 were $48.6 million vs. total current liabilities of $4.2 million for a 12:1 current ratio.  We continue to fund our business from our free cash flow.  As of September 30, 2012, we had cash and cash equivalents of approximately $12.1 million compared with approximately $17 million at 2011 year-end."

Mr. Wang concluded, "Despite the temporary setback, our business remains solid.  We are confident that as a result of our efforts, our sales will continue to gradually recover in the coming months.  Based on net sales recorded for the month of October and first half of November, and we expect 2012 fourth quarter sales to be significantly higher than 2012 third quarter."

Conference Call

Biostar's Chairman and CEO, Ronghua Wang and CFO, Zack Pan will host a conference call on Monday, November 19, 2012 at 9:30 am ET / 10:30 pm China time to discuss these results as well as recent corporate developments.

Live conference call details

Interested parties may participate in the call by dialing (480) 629-9712.  Please call in 10 minutes before the conference is scheduled to begin and ask for the Biostar call or use pass code 4576907.  After opening remarks, there will be a question and answer period.  Questions may be asked during the live call, or alternatively, you may e-mail questions in advance to [email protected].

Webcast

The conference call will also be broadcast live over the Internet.  To listen to the webcast, please go to http://public.viavid.com/index.php?id=102669 or visit Biostar's website http://www.biostarpharmaceuticals.com and then to the Event Calendar page where the conference call is posted.  Please go to the website at least 15 minutes early to register, and download and install any necessary audio software.  If you are unable to listen live, the conference call will be archived and can be accessed for approximately 90 days.  We suggest listeners use Microsoft Internet Explorer as their web browser.

Replay

A replay will be available until 11:59 pm E.T. on November 26, 2012. To listen, please call (858) 384-5517 and use pass code 4576907.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to recover its sales following the SFDA investigation in the 3rd quarter of 2012 and for the year ended, the Company's ability to integrate the recently acquired Shaanxi Weinan product lines into the Company's current product line and current operations, the state of consumer confidence and market demand or the Company's products,  success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders.  We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.  

For more information contact:


BioStar Pharmaceuticals, Inc.

The Equity Group, Inc.

Zack Pan, CFO

Lena Cati

Tel: 405-996-8829

Tel: 212 836-9611

Email: [email protected]

Email: [email protected]

~FINANCIAL TABLES FOLLOW~


 

BIOSTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 



Three Months Ended


Nine Months Ended



September 30,


September 30,



2012



2011


2012



2011














Sales, net

$

9,969,375



$

24,779,420


$

34,028,164



$

65,980,481

















Cost of sales                                               


4,729,894




7,465,966



13,379,287




19,352,264

















Gross profit


5,239,481




17,313,454



20,648,877




46,628,217

















Operating expenses:















   Selling expenses


6,009,227




10,391,335



18,498,671




26,908,239


   General and administrative expenses


2,640,240




983,778



5,124,789




4,103,154


   Credits for negative publicity


-




-



7,904,513




-


   Administrative penalty


1,596,174




-



1,596,174




-


   Research and development expenses


789,702




-



2,370,605




-

















           Total operating expenses


11,035,343




11,375,113



35,494,752




31,011,393

















(Loss) Income from operations


(5,795,862)




5,938,341



(14,845,875)




15,616,824

















Other income (expense)















  Interest income


55,642




127,423



247,342




271,737


  Interest expense


(1,059)




(2,984)



(33,193)




(10,371)


  Other income


152




273



598




821


Total other income (expenses)


54,735




124,712



214,747




262,187

















(Loss) Income before income taxes


(5,741,127)




6,063,053



(14,631,128)




15,879,011

















Income tax expenses (benefits)


198,508




1,599,316



(1,376,356)




4,539,127

















Net (loss) income


(5,939,635)




4,463,737



(13,254,772)




11,339,884

















Other comprehensive income















 Foreign currency translation adjustment


(117,289)




640,119



180,992




1,733,586

















Total comprehensive (loss) income

$

(6,056,924)



$

5,103,856


$

(13,073,780)



$

13,073,470
































(Loss) Earnings per share, on net income















  Basic

$

(0.63)



$

0.47


$

(1.41)



$

1.22


  Diluted

$

(0.63)



$

0.47


$

(1.41)



$

1.22

















Weighted average number of common 
  stock outstanding















  Basic


9,490,506




9,398,876



9,430,532




9,264,104


  Diluted


9,490,506




9,398,876



9,430,532




9,264,104


















 

 

BIOSTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 




September 30,



December 31,




2012



2011




(Unaudited)





ASSETS







Current Assets







  Cash and cash equivalents


$

12,119,565



$

16,971,789


  Accounts receivable



28,815,263




35,033,650


  Inventories



985,274




1,373,459


  Tax prepaid



451,121




-


  Prepaid expenses and other receivables



5,390,773




7,129,911


  Prepaid research and development expenses



789,390




-


     Total Current Assets



48,551,386




60,508,809











Deposits



-




3,148,466


Deferred tax assets



3,328,228




1,617,688


Property and equipment, net



7,038,982




7,379,982


Intangible assets, net



9,390,806




10,406,931


     Total Assets


$

68,309,402



$

83,061,876











LIABILITIES AND STOCKHOLDERS' EQUITY


















Current Liabilities









Accounts and other payables


$

3,644,084



$

3,334,418


Short-term bank loans



-




787,116


Value-added tax payable



451,088




895,487


Income tax payable



92,677




1,643,155


     Total Current Liabilities



4,187,849




6,660,176











Commitment and contingencies                                                      


















Stockholders' Equity









  Common stock, $0.001 par value, 100,000,000 shares authorized,









      9,993,549 and 9,400,216 shares issued and outstanding as of
      September 30, 2012 and December 31, 2011*



9,993




9,400


  Additional paid-in capital



23,238,700




22,445,660


  Statutory reserve



6,490,600




6,490,600


  Retained earnings



30,219,062




43,473,834


  Accumulated other comprehensive income



4,163,198




3,982,206


     Total Stockholders' Equity



64,121,553




76,401,700











     Total Liabilities and Stockholders' Equity


$

68,309,402



$

83,061,876




















*Number of shares issued and outstanding retroactively reflects reverse stock split effective on April 3, 2012











  

SOURCE Biostar Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foreseeable future it's going to get a whole lot harder. Everything you know today will change. Keeping up with this changing landscape is already a daunting task. Your organization needs to use the latest tools, methods and expertise to guard against those threats. But will that be enough? In the foreseeable future attacks w...
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize supplier management. Learn about enterprise architecture strategies for designing connected systems tha...
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the areas of search, content management, and NoSQL, and includes senior roles in technical marketing, sales engineering, and support engineering. Dale holds an MBA from Santa Clara University, and a BA in Computer Science from the University of California, Berkeley.
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of presentation. In her session at @ThingsExpo, Jocelyn Scheirer, CEO & Founder of Bionolux, will discuss ho...
The cloud is now a fact of life but generating recurring revenues that are driven by solutions and services on a consumption model have been hard to implement, until now. In their session at 16th Cloud Expo, Ermanno Bonifazi, CEO & Founder of Solgenia, and Ian Khan, Global Strategic Positioning & Brand Manager at Solgenia, will discuss how a top European telco has leveraged the innovative recurring revenue generating capability of the consumption cloud to enable a unique cloud monetization model to drive results.
As organizations shift toward IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection &E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 16th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships, will discuss how to cut costs, scale easily, and unleash insight with CommVault Simpana software, the only si...
Analytics is the foundation of smart data and now, with the ability to run Hadoop directly on smart storage systems like Cloudian HyperStore, enterprises will gain huge business advantages in terms of scalability, efficiency and cost savings as they move closer to realizing the potential of the Internet of Things. In his session at 16th Cloud Expo, Paul Turner, technology evangelist and CMO at Cloudian, Inc., will discuss the revolutionary notion that the storage world is transitioning from mere Big Data to smart data. He will argue that today’s hybrid cloud storage solutions, with commodity...
Every innovation or invention was originally a daydream. You like to imagine a “what-if” scenario. And with all the attention being paid to the so-called Internet of Things (IoT) you don’t have to stretch the imagination too much to see how this may impact commercial and homeowners insurance. We’re beyond the point of accepting this as a leap of faith. The groundwork is laid. Now it’s just a matter of time. We can thank the inventors of smart thermostats for developing a practical business application that everyone can relate to. Gone are the salad days of smart home apps, the early chalkb...
Cloud data governance was previously an avoided function when cloud deployments were relatively small. With the rapid adoption in public cloud – both rogue and sanctioned, it’s not uncommon to find regulated data dumped into public cloud and unprotected. This is why enterprises and cloud providers alike need to embrace a cloud data governance function and map policies, processes and technology controls accordingly. In her session at 15th Cloud Expo, Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems, will focus on how to set up a cloud data governance program and s...
Roberto Medrano, Executive Vice President at SOA Software, had reached 30,000 page views on his home page - http://RobertoMedrano.SYS-CON.com/ - on the SYS-CON family of online magazines, which includes Cloud Computing Journal, Internet of Things Journal, Big Data Journal, and SOA World Magazine. He is a recognized executive in the information technology fields of SOA, internet security, governance, and compliance. He has extensive experience with both start-ups and large companies, having been involved at the beginning of four IT industries: EDA, Open Systems, Computer Security and now SOA.
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focused on understanding how industrial data can create intelligence for industrial operations. Imagine ...
We certainly live in interesting technological times. And no more interesting than the current competing IoT standards for connectivity. Various standards bodies, approaches, and ecosystems are vying for mindshare and positioning for a competitive edge. It is clear that when the dust settles, we will have new protocols, evolved protocols, that will change the way we interact with devices and infrastructure. We will also have evolved web protocols, like HTTP/2, that will be changing the very core of our infrastructures. At the same time, we have old approaches made new again like micro-services...
Operational Hadoop and the Lambda Architecture for Streaming Data Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, representing a model of how to analyze rea...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes for use cases across the industrial, enterprise, and consumer segments.
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile devices as well as laptops and desktops using a visual drag-and-drop application – and eForms-buildi...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch of Docker's initial release in March of 2013, interest was revved up several notches. Then late last...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures traffic gets delivered faster, safer, and more reliably than ever.
CommVault has announced that top industry technology visionaries have joined its leadership team. The addition of leaders from companies such as Oracle, SAP, Microsoft, Cisco, PwC and EMC signals the continuation of CommVault Next, the company's business transformation for sales, go-to-market strategies, pricing and packaging and technology innovation. The company also announced that it had realigned its structure to create business units to more directly match how customers evaluate, deploy, operate, and purchase technology.
In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect at GE, and Ibrahim Gokcen, who leads GE's advanced IoT analytics, focused on the Internet of Things / Industrial Internet and how to make it operational for business end-users. Learn about the challenges posed by machine and sensor data and how to marry it with enterprise data. They also discussed the tips and tricks to provide the Industrial Internet as an end-user consumable service using Big Data Analytics and Industrial Cloud.
The explosion of connected devices / sensors is creating an ever-expanding set of new and valuable data. In parallel the emerging capability of Big Data technologies to store, access, analyze, and react to this data is producing changes in business models under the umbrella of the Internet of Things (IoT). In particular within the Insurance industry, IoT appears positioned to enable deep changes by altering relationships between insurers, distributors, and the insured. In his session at @ThingsExpo, Michael Sick, a Senior Manager and Big Data Architect within Ernst and Young's Financial Servi...